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Abstract
Background: Patients with end stage liver disease are characteristically malnourished which is
associated with poor outcome. Formulas enriched with arginine, ω-3 fatty acids, and nucleotides,
"immunonutrients", potentially improve their nutritional status. This study is designed to evaluate
the clinical outcome of long-term "immunonutrition" of patients with end-stage liver disease while
on the waiting list for liver transplantation.
Methods/design:  A randomized controlled double blind multi-center clinical trial with two
parallel groups comprising a total of 142 newly registered patients for primary liver transplantation
has been designed to assess the safety and efficacy of the long-term administration of ORAL
IMPACT®, an "immunonutrient" formula, while waiting for a graft. Patients will be enrolled the day
of registration on the waiting list for liver transplantation. Study ends on the day of transplantation.
Primary endpoints include improved patients' nutritional and physiological status, as measured by
mid-arm muscle area, triceps skin fold thickness, grip strength, and fatigue score, as well as patients'
health related quality of life. Furthermore, patients will be followed for 12 postoperative weeks to
evaluate anabolic recovery after transplantation as shown by reduced post-transplant mechanical
ventilation, hospital stay, wound healing, infectious morbidities (pneumonia, intraabdominal
abscess, sepsis, line sepsis, wound infection, and urinary tract infection), acute and chronic
rejection, and mortality.
Discussion: Formulas enriched with arginine, ω-3 fatty acids, and nucleotides have been proven
to be beneficial in reducing postoperative infectious complications and length of hospital stay
among the patients undergoing elective gastrointestinal surgery. Possible mechanisms include
downregulation of the inflammatory responses to surgery and immune modulation rather than a
sole nutritional effect.
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Trials 2007, 8:20 doi:10.1186/1745-6215-8-20
Received: 10 July 2007
Accepted: 27 August 2007
This article is available from: http://www.trialsjournal.com/content/8/1/20
© 2007 Nickkholgh et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Trials 2007, 8:20 http://www.trialsjournal.com/content/8/1/20
Page 2 of 9
(page number not for citation purposes)
Background
Immunonutrition
Patients with end-stage liver disease (ESLD) characteristi-
cally suffer from protein-energy malnutrition (PEM) and
hypermetabolism due to abnormal nutrient and caloric
intake, decreased intestinal absorption, and metabolic
disturbances, which is associated with poor outcome
including poor perceived health-related quality of life
(HRQL) [1,2] and unsatisfactory postoperative course,
i.e., prolonged intensive care unit and total hospital stay,
prolonged mechanical ventilation, and increased morbid-
ities and mortality [3,4]. The biochemical nutritional
derangements include deficiency in ω-3 and ω-6 long-
chain fatty acids [5], insulin resistance [6], growth hor-
mone resistance [7,8], increased proinflammatory
cytokines (e.g., TNF-α, IL-1, IL-6) [9], and increased lipid
peroxidation due to a deficiency in endogenous antioxi-
dants, i.e. vitamin E and carotenoids [10,11], all of which
lead to a clinical manifestation of progressive lipolysis
and proteolysis. Supplementation with ω-3 fatty acids
may downregulate proinflammatory cytokine production
and modulate eicosanoid synthesis [12-14]. The latter
molecules lead to the production of vasodilators, i.e.
LTB5, PGE3, PGI3, and TxA3, thus acting against inflam-
mation, aggregation, adhesion, and chemotaxis [15].
Arginine, which cannot be produced in catabolic states,
stimulates the release of anabolic hormones (growth hor-
mone, insulin), improves nitrogen balance and wound
healing, upregulates immune function, and enhances NO
biosynthesis [16-18]. An increase in protein synthesis can
be achieved with nucleotides [19]. Nucleotides can also
enhance a variety of host defense mechanisms [20]. For-
mulas enriched with arginine, ω-3 fatty acids, and nucle-
otides (immune enhancing diets or the so-called
"immunonutrients" – which are designed to modulate a
patient's immune response and can hence augment basic
nutritional repletion) have been proven to be beneficial in
reducing postoperative infectious complications and
length of hospital stay among the patients undergoing
elective gastrointestinal surgery, especially in those who
are malnourished preoperatively [21]. Possible mecha-
nisms include downregulation of the inflammatory
responses to surgery and immune modulation rather than
a sole nutritional effect.
Trial Rationale
The interval between listing and transplantation, which
may usually extend to several months, provides a unique
opportunity for the physician to institute a nutritional
therapy. However, clinical studies concerning the long-
term preoperative supplementation with such immune-
modulating formulas in the field of transplant surgery are
rare and inconclusive. Up to 30 papers between 1995 and
2005 under the topic of "immunonutrition and surgery"
were found in the literature and reviewed. However, none
investigated the long-term preoperative outcome of such
supplementation (all just covered a short-term peri- or
postoperative period), and few, if any, directly considered
the liver transplant patients. Concerning the supplemen-
tation of the patients in the waiting list for transplanta-
tion, 4 studies were found in the literature, of which only
one was randomized. The latter trial investigated the pre-
operative nutritional supplementation in patients await-
ing elective orthotopic liver transplantation (LT) and was
designed to determine whether nutritional supplementa-
tion improves nutritional status and affects outcome after
transplantation. However, it failed to reveal any signifi-
cant effect on outcome after transplantation, although it
improved some parameters of nutritional status pretrans-
plantation. The investigators didn't use any immune-
enhancing diet in the trial [22].
Preliminary results of a recent nonrandomized pilot study
suggest that immunonutrition may improve short-term
preoperative nutritional status, hasten recovery after
transplantation, and reduce postoperative infectious com-
plications [23]. Preoperative feeding was started after
patients got to the top of the waiting list (and was contin-
ued for at least 5 days posttransplant). ORAL IMPACT®
(Novartis Consumer Health, Nyon, Switzerland) was used
with no adverse short-term consequences.
Therefore, this study is unique because it is randomized
and it fully investigates the effects of ORAL IMPACT® dur-
ing a long-term period in patients waiting for a LT. In this
manner, the comparison between patients receiving
ORAL IMPACT®  (arginine/ω-3 fatty acids/nucleotide
enriched formula) or an isocaloric isonitrogenous control




After the positive vote of the ethics committee of the Fac-
ulty of Medicine, Ruprecht-Karls University of Heidelberg,
enrollment of 142 newly registered patients for primary
LT will be started early in September 2007 in this prospec-
tive multicenter placebo-controlled randomized double-
blind clinical trial with two parallel treatment groups
receiving either study product or control supplement.
Patients are considered for recruitment to the study
according to inclusion and exclusion criteria (Table 1).
Each subject is expected to be recruited on the day of reg-
istration on the waiting list for LT. Study nutrition ends on
the day of transplantation. To assess early outcome after
transplantation patients are followed for 12 postoperative
weeks. The duration of the overall trial is expected to last
approximately 36 months. The actual duration of trial
may vary due to the availability of patients meeting the
criteria after registration for LT.Trials 2007, 8:20 http://www.trialsjournal.com/content/8/1/20
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Objectives and endpoints
Primary objective is to determine the safety and efficacy of
the long-term administration of immunonutrients, and
assessment of the patients' nutritional and physiological
status as well as quality of life, while waiting for a graft.
Secondary Objective is to investigate the effects of immu-
nonutrition on post-transplant morbidities.
Trial design and schedule (Fig. 1)
Site number, patients' randomization number and ini-
tials, all demographic data (date of birth, sex, height,
weight), medical history (including a complete dietary
history and MELD score), physical examination, comor-
bidities, and concomitant medications are documented
on day one. Furthermore, anthropometric, physiologic,
and biochemical measurements are carried out and docu-
mented. The aforementioned measurements are per-
formed during monthly visits until transplantation. The
patients consume either the study product (ORAL
IMPACT®) (Table 2) or control product (IMPACT-control
supplement) (Table 2) once a day for the period of wait-
ing until a graft is available. During each visit, the follow-
ing data are recorded in the electronic case report form
(eCRF):
A. Anthropometric measurements, including:
• Body weight (BW, kg),
• Body mass index (BMI),
• Mid-arm muscle area (MAMA, cm2)
• Mid-arm circumference (MAC, cm),
• Mid-arm muscle circumference (MAMC (cm) = MAC
(cm) - [0.314 × TSF (mm)]),
• Triceps skinfold thickness (TSF, mm),
• Lean body mass (LBM, kg), and
• Creatinine height index (CHI, %) from 24-hour urinary
creatinine excretion (patients are advised to collect their
urine for 24 hours right before each monthly visit and
bring it to the center with them)
B. Biochemical parameters, including albumin, bilirubin,
creatinine, urea, alkaline phosphatase, transaminases
(ALT, AST), INR, phosphate, transferrin, total body potas-
sium)
C. Endocrine measurements, including fasting insulin,
GH, and IGF-1
D. Resting energy expenditure (REE, kcal/d) by indirect
calorimetry
E. Voluntary muscle function: grip strength (kg)
F. Respiratory function: Peak expiratory flow rates
G. Fatigue score and HRQL (SF-36 questionnaires [24]).
During each monthly visit, patients will be provided with
the required monthly amount of study product (or con-
trol product) and are asked to return the emptied study
boxes with them to the next monthly session to warrant
that they are compliant with the trial regimen. Further,
between the two consecutive monthly visits, the trial
investigator has to phone call the patient weekly to check
for both compliance and adverse events. Deviations of the
protocol are documented in the eCRF. The trial ends on
the day a graft becomes available. A patient consuming a
total of 80% of the calories prescribed over the entire pre-
operative study period is considered a "completer". Post-
transplant investigations concern anabolic recovery after
transplantation as shown by:
• post-transplant mechanical ventilation
• total hospital stay
• wound healing
Table 1: Criteria for inclusion and exclusion of patients.
Inclusion criteria Exclusion criteria
patients meeting all of the following criteria are considered for inclusion 
in the study:
- men and women, 18–68 years of age
- scheduled for first liver transplantation
- written informed consent
- protein-calorie malnutrition defined as mid-arm muscle area (MAMA) 
<85% standard
patients with any of the following will not be included in the trial:
- patients <18 and >68 years
- pregnant or nursing women
- history of hypersensitivity to arginine, ω-3 fatty acids, or nucleotides
- inability to take oral nutrition
- patients with fulminant or subacute hepatic failure
- mental condition rendering the subject incapable of understanding the 
nature, scope, and consequences of the trial
No subject will be enrolled in this study more than once.Trials 2007, 8:20 http://www.trialsjournal.com/content/8/1/20
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• infectious morbidities (pneumonia, intraabdominal
abscess, sepsis, central line sepsis, wound infection, and
urinary tract infection)
• CRP levels
• acute and chronic rejection, and
• mortality (ICU mortality, hospital mortality, 28-day
mortality, and survival at the 12th week post-transplant
surveillance period).
These post-transplant parameters are investigated and
documented during the patients' posttransplant hospital
stay daily and further until the 12th week posttransplant
Scheme depicting the workflow of the study Figure 1
Scheme depicting the workflow of the study. Each subject will be recruited on the day of registration on the waiting list 
for liver transplantation after giving informed consent. Study nutrition ends on the day of transplantation. Subjects are rand-
omized to two parallel groups treated for study or control product. Furthermore, patients will be followed for 12 weeks after 
transplantation.
PROUD STUDY
Monthly evaluation of patients
Telephone calls for monitoring between sessions
1. Medical history and co-morbidities 
2. Concomitant medication
3. Physical examination
4. Anthropometric measurements, including:
Body weight (BW, kg),
Body mass index (BMI),
Mid-arm muscle area (MAMA, cm2),
Mid-arm circumference (MAC, cm),
Mid-arm muscle circumference (MAMC (cm)=MAC (cm)-[0.314×TSF (mm)]),
Triceps skin fold thickness (TSF, mm),
Lean body mass (LBM, kg), and
Creatinine height index (CHI, %) from 24-hour urinary creatinine excretion
5. Biochemical parameters, including albumin, bilirubin, creatinine, urea, alkaline 
phosphatase, aspartate transaminase, INR (International Normalized Ratio), 
phosphate, transferrin, total body potassium)
6. Endocrine measurements, including fasting insulin, GH, IGF-1
7. Resting energy expenditure (REE, kcal/d) by indirect calorimetry
8. Voluntary muscle function: grip strength (kg)
9. Respiratory function: Peak expiratory flow rates
10. Fatigue score and Health Related Quality of Life (SF-36 or SIP questionnaires)
11. Final assessment
12. Compliance check
Anabolic recovery after transplantation 










and urinary tract infection), 
CRP,
acute and chronic rejection, and
mortality (ICU mortality, hospital mortality, 
28-day mortality, and survival at the 12th week 
post-transplant surveillance period) 
Registration for Primary LTx
Informed consent
Day of LTx:  Nutrition ends End of 12th Wk: 
Post-transplant Study ends hereTrials 2007, 8:20 http://www.trialsjournal.com/content/8/1/20
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through postoperative follow-up sessions. Sepsis is
defined as the presence of at least 2 out of the following 4
criteria: (1) temperature >38°C or <36°C, (2) tachycardia
>90/min, (3) leukocytosis >12/nl or leukopenia <4/nl,
and (4) respiratory insufficiency (any of the 3 following
criteria: respiratory rate >20/min, hyperventilation with
PaCO2 <32 mmHg or PaO2 <70 mmHg (spontaneous
breathing) or PaO2/FiO2 <175 mmHg (mechanical venti-
lation) [25]. CRP will be measured weekly posttransplant
until the patient is discharged, and then along with other
investigations through postoperative follow-up sessions.
During the posttransplant phase, subjects will routinely
receive immunosuppressive therapy which includes
cyclosporine A, mycophenolate (Myfortic®) and steroids.
The immunosuppression will be done with or without
induction therapy [Simulect® (Basiliximab)].
Sample size calculation
The sample size calculation is based on the detection of
significant differences in MAMA, one of the primary end-
point parameters of this trial. A clinical trial on enteral
hyperalimentation in malnourished patients with cirrho-
sis and ascites [26] was used as an exemplary model. The
rate was measured in percent per day, i.e. MAMA changes
divided by number of days between admission and dis-
charge. After eliminating the gross outlier of this study, the
standard deviation of this rate was 0.21% per day. The
clinically relevant difference was set to 0.1% MAMA per
day. Therefore, the sample size necessary for the trial with
a power of 80% and a two-sided significance level of 0.05
was calculated to be 71 patients per group. An assumed
10% drop-out rate in this trial (due to non-compliance,
intolerance, premature discontinuation, etc) will raise the
sample size to 78 patients per group. Therefore, at least a
total of 156 patients have to be included to the trial in
order to yield 142 completers.
Randomization and treatment
Randomization (1:1) will be performed by the algorithm
programmed in specific computer software and a rand-
omization list will be prepared. The randomization list
will be prepared by the institution that is responsible for
the packaging of the study and control products and kept
in safe and confidential custody at this institution. Both
study product and control product will be of same form
and appearance (powder) including the packaging mate-
rial. If it is medically imperative to know which product
the patient consumes, emergency envelopes contain the
information on the subject's study product.
Adverse events
All adverse events (AE) are recorded. Events related to the
initial diagnosis for LT, to the transplantation procedure
itself, or problems associated with routine procedures
after transplantation, e.g., liver biopsy, are not to be noted
as AE or serious adverse event (SAE) unless the investiga-
tor deems the events to be a cause of the study product. All
SAE potentially associated with the application of study
product must be documented on a SAE form which has to
be sent to the principal investigator within 24 hours or lat-
Table 2: Composition of ORAL IMPACT® †and IMPACT Control 
supplement (in powder form)





-Protein g 16.7 13.0
-Casein/Whey g (13) (13)
-L Arginine g (3.74) -
-Fat g 8.3 8.3
-Essential FA (LA+LNA) g (0.94) (2.6)
-n-6-FA (LA) g (0.74) (2.6)
-n-3FA 
(EPA+DHA+LNA)
g( 1 ) -
Carbohydrates g 40.2 43.94
Fibres g 3 3
RNA mg 390 -
Energy g 302.8 302.8
-kcal/ml § §
-P:F:C % 22:25:53 17:25:58
Sodium mg 320 320
Potassium mg 402 402
Calcium mg 240 240
Magnesium mg 80 80
Phosphorus mg 216 216
Chloride mg 480 480
Iron mg 3.6 3.6
Copper mg 0.5 0.5
Manganese mg 0.6 0.6
Zinc mg 4.5 4.5
Fluoride mg 0.5 0.5
Iodine mcg 45 45
Chromium mcg 30 30
Molybdenum mcg 60 60
Selenium mcg 14 14
Retinol (Vit. A.) mg 0.3 0.3
Calciferol (Vit. D) mcg 2 2
Tocopherol (Vit. E) mg 4 4
Phyllochin. (Vit. K1) mg 20 20
Thiamine (Vit. B1) mg 0.36 0.36
Riboflavine (Vit. B2) mg 0.52 0.52
Pyridoxine (Vit. B6) mg 0.44 0.44
Cyanocobal. (Vit. B12) mcg 1.2 1.2
Ascorbic Acid (Vit. C) mg 20 20
Biotin mcg 30 30
Folic Acid mcg 60 60
Niacinamide mg 4.8 4.8
Pantothenic Acid mg 2.4 2.4
†; IMPACT® is a food for special medical purpose (FSMP)
§ content of sachet to be dissolved in 250 ml water for each serving
FA; fatty acid, LA; linoleic acid, LNA; linolenic acid, EPA; 
Eicosapentaenoic acid, DHA; docosahexaenoic acid, RNA; ribonucleic 
acid, kcal; kilocalorie, ml; millilitre, P:F:C; protein:fat: carbohydrate, 
Vit.; vitamin.
Reference: http://www.novartis-nutrition.deTrials 2007, 8:20 http://www.trialsjournal.com/content/8/1/20
Page 6 of 9
(page number not for citation purposes)
est on the following working day. The principal investiga-
tor ensures that SAE are reported to the safety board,
ethics committee, and to further investigators, if applica-
ble.
Quality assurance
The study is performed according to the principles of the
ICH-GCP consolidated guidelines as required by regula-
tory agencies [27] and the ethical principles according to
the current revision of the Declaration of Helsinki [28]
and local legal and regulatory requirements. The trial is
monitored by HealthEcon AG according to standard oper-
ational procedures that is based on ICH-GCP guidelines.
An independent safety board monitors closely the proper
conduct of the trial and all SAE reports to ensure the safety
of the subjects during the course of the study.
Statistics and data management
All analyses will be carried out on an "intent-to-treat"
basis. However, attempts will be made to analyze "per
protocol", "completer", and "intent-to-treat" populations
separately, when statistically appropriate. Repeated-meas-
ures analysis of variance (ANOVA) will be used followed
by t-test when significant differences are detected by
ANOVA. Pearson Chi-square test or Fisher's exact test will
be used when appropriate. Times to an event are described
by Kaplan-Meier and compared between groups by the
log-rank test. The differences of the analysis variables are
tested with the paired t-test or, in case of uneven distribu-
tion, the Wilcoxon-test (2-sided) for within group com-
parison. The Mann-Whitney U test will be used to detect
differences between study groups. The following statistical
values will be calculated where appropriate: mean, stand-
ard deviation, 95%-confidence interval of the mean, min-
imum, lower quartile, median, upper quartile, maximum,
valid number, frequency count, and percentage. The labo-
ratory values will be counted according to their normal
ranges (below normal, normal, and above normal). Bio-
metric analysis will be defined in the statistical analysis
plan which has to be authorized before unblinding by the
biometrician, the sponsor, and the principal investigator.
One interim analysis will be performed after half of the
patients have finished the clinical period for the primary
endpoints.
All patient data (clinical and resource use) generated dur-
ing the study will be recorded on the eCRFs specifically
designed to meet the data recording requirements of the
clinical study protocol provided by HealthEcon AG. All
data management activities will be done according to
ICH-GCP guidelines. Responsibility for data management
is with HealthEcon AG, Basel, Switzerland. Throughout
the study, all patient information in the eCRF will only be
identifiable by means of an identification number
(patient number) and possibly patient initials.
Discussion
PEM is common in ESLD, with the prevalence ranging
from 20% to 60% or even higher depending on the sever-
ity of liver insufficiency and the method of assessment.
The prevalence and degree of PEM do not seem to relate
to the etiology of liver disease per se [29]. In order to com-
pletely assess the nutritional status of the patients with
ESLD, it is essential to obtain detailed information on
body cell mass, biochemical function, and basal metabo-
lism of the patients.
Muscle wasting is a major feature of malnutrition in ESLD
[30], and is almost always present in patients waiting for
LT [31]. Anthropometric evaluation of upper limbs is a
simple, convenient, valuable, rapid, noninvasive, and
inexpensive way to assess nutritional status, and it is easy
to repeat during the follow-up period [32]. Combined
anthropometric measurements of arm circumference and
triceps skinfold thickness and calculation of arm muscle
area are useful tools for the assessment of body muscle
mass, which, together with fat mass, decrease in ESLD due
to PEM and subsequent enhanced gluconeogenesis and
protein breakdown. The decrease in muscle mass is greater
than the reduction of body weight [33,34]. Also, mid-arm
muscle circumference and handgrip strength measure-
ments appear to be sensitive markers of body cell mass
depletion [35] whereas triceps skinfold thickness provides
a good clinical assessment of the fat body mass [36]. Uri-
nary creatinine excretion correlates significantly with
anthropometrically estimated muscle mass. However, it
should be interpreted cautiously in the presence of coex-
isting renal dysfunction [37]. Although for a precise quan-
tification of malnutrition in patients with ESLD, direct
methods such as in vivo neutron activation analysis, dual-
energy x-ray absorptiometry, or deuterium oxide dilution
(to determine total body nitrogen, fat, and water, respec-
tively) are preferred [38], these methods are expensive,
not readily available, and therefore their use is not justifi-
able for a long-term clinical trial. Moreover, even the accu-
racy of such tests may be affected by fluid retention [3].
Laboratory tests can indicate the liver dysfunction, and the
consequent biochemical derangements. Basal metabo-
lism should be measured by indirect calorimetry, and if
not available, may be calculated from Harris and Bene-
dict's equation [39]. Ideal body weight may be accepted
for calculation means [29]. Voluntary muscle function has
been shown to be an independent predictor of outcome
in alcoholic liver disease [40] and therefore may be useful
as an objective tool to assess the response to nutrition in
ESLD [41]. The "medical outcomes study short form 36"
(SF-36) is a widely used and validated generic HRQL ques-
tionnaire [42-44].Trials 2007, 8:20 http://www.trialsjournal.com/content/8/1/20
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In order to establish a nutritional support, an ideal prod-
uct is what has undergone an extensive evaluation for
safety and efficacy through prospective randomized clini-
cal trials. Considerable evidence supports that IMPACT®
specialized nutrition support positively influences inflam-
matory, metabolic, and immune responses to major sur-
gery [45]. However, any nutrient that can alter immune
function deserves critical evaluation for potential adverse
effects. Up to now, no adverse effects has been reported in
patients supplemented with IMPACT® [45]. Concerning
the L-Arginine content of IMPACT® and its use in patients
with ESLD, a recent pilot study on fifteen patients with
ESLD receiving two 74 g sachets of ORAL IMPACT® (each
containing 3.74 g L-Arginine) daily (twice as much as the
daily administered amount in current study) for a median
of 54 (range 10–168) days pre-transplant showed no
adverse consequences that could be attributed to the
nutritional product [23]. Furthermore, the total protein
content of IMPACT® is 16 g, which is far below the 1.2 g/
kg daily protein requirement of the patients with ESLD
[29].
Conclusion
This randomized controlled trial is intended to investigate
the long-term preoperative effects of ORAL IMPACT® on
the nutritional status as well as the outcome of the
patients with ESLD listed for transplantation. The working
hypothesis is that Oral IMPACT® has the ability to down-
regulate the inflammatory responses to chronic disease
and surgery through immune modulation. Safety and effi-
cacy, anthropometric and physiological parameters,
HRQL, as well as post-transplant morbidities and survival
will be assessed.
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